CSF biomarkers Compared for Down Syndrome and Inherited Alzheimer’s
By LabMedica International staff writers Posted on 19 Aug 2021 |
Image: Representative example of amyloid-β plaques (Aβ1-42; brown staining; arrowheads) and neurofibrillary tangles (PHF1 antibody; blue staining; arrow) in the frontal cortex of a 46-year-old person with Down syndrome and end-stage Alzheimer disease. (Photo courtesy of University of California, Irvine).
Although most people with Down’s syndrome will experience brain changes as they age, not everyone will develop Alzheimer’s disease or another type of dementia. Whilst having Down’s syndrome does put a person at increased risk, estimated at 1 in 3 people in their 50s, and closer to 2 in 3 aged over 60, it is not inevitable for all.
Due to trisomy of chromosome 21 and the resultant extra copy of the amyloid precursor protein gene, nearly all adults with Down syndrome develop Alzheimer's disease pathology by the age of 40 years and are at high risk for dementia given their increased life expectancy compared with adults with Down syndrome in the past.
A large team of Neuroscientists led by those at Washington University School of Medicine (St. Louis, MO, USA) and their colleagues carried out a cross-sectional study that included 341 individuals (178 [52%] women, 163 [48%] men, aged 30–61 years). Participants were 41 adults with Down syndrome, similarly aged carriers of autosomal dominant Alzheimer's disease mutations (n=192), and non-carrier siblings (n=108). Participants with baseline cerebrospinal fluid (CSF), available clinical diagnosis, and apolipoprotein E genotype as of January 31, 2019, were included in the analysis.
CSF samples obtained from adults with Down syndrome, similarly aged carriers of autosomal dominant Alzheimer's disease mutations, and non-carrier siblings (aged 30–61 years) were analyzed for markers of amyloid β (Aβ1–40, Aβ1–42); tau phosphorylated at threonine 181-related processes; neuronal, axonal, or synaptic injury (total tau, visinin-like protein 1, neurofilament light chain [NfL], synaptosomal-associated protein 25); and astrogliosis and neuroinflammation (chitinase-3-like protein 1 [YKL-40]) via immunoassay.
The team reported that individuals with Down syndrome had patterns of Alzheimer's disease-related CSF biomarkers remarkably similar to carriers of autosomal dominant Alzheimer's disease mutations, including reductions in Aβ 1-42 to Aβ 1-40 ratio and increases in markers of phosphorylated tau-related processes; neuronal, axonal, and synaptic injury; and astrogliosis and neuroinflammation, with greater degrees of abnormality in individuals with dementia. Differences included overall higher concentrations of Aβ and YKL-40 in Down syndrome and potential elevations in CSF tau and NfL in the asymptomatic stage (i.e., no dementia symptoms). The study was published in the August edition of the journal Lancet Neurology.
Related Links:
Washington University School of Medicine
Due to trisomy of chromosome 21 and the resultant extra copy of the amyloid precursor protein gene, nearly all adults with Down syndrome develop Alzheimer's disease pathology by the age of 40 years and are at high risk for dementia given their increased life expectancy compared with adults with Down syndrome in the past.
A large team of Neuroscientists led by those at Washington University School of Medicine (St. Louis, MO, USA) and their colleagues carried out a cross-sectional study that included 341 individuals (178 [52%] women, 163 [48%] men, aged 30–61 years). Participants were 41 adults with Down syndrome, similarly aged carriers of autosomal dominant Alzheimer's disease mutations (n=192), and non-carrier siblings (n=108). Participants with baseline cerebrospinal fluid (CSF), available clinical diagnosis, and apolipoprotein E genotype as of January 31, 2019, were included in the analysis.
CSF samples obtained from adults with Down syndrome, similarly aged carriers of autosomal dominant Alzheimer's disease mutations, and non-carrier siblings (aged 30–61 years) were analyzed for markers of amyloid β (Aβ1–40, Aβ1–42); tau phosphorylated at threonine 181-related processes; neuronal, axonal, or synaptic injury (total tau, visinin-like protein 1, neurofilament light chain [NfL], synaptosomal-associated protein 25); and astrogliosis and neuroinflammation (chitinase-3-like protein 1 [YKL-40]) via immunoassay.
The team reported that individuals with Down syndrome had patterns of Alzheimer's disease-related CSF biomarkers remarkably similar to carriers of autosomal dominant Alzheimer's disease mutations, including reductions in Aβ 1-42 to Aβ 1-40 ratio and increases in markers of phosphorylated tau-related processes; neuronal, axonal, and synaptic injury; and astrogliosis and neuroinflammation, with greater degrees of abnormality in individuals with dementia. Differences included overall higher concentrations of Aβ and YKL-40 in Down syndrome and potential elevations in CSF tau and NfL in the asymptomatic stage (i.e., no dementia symptoms). The study was published in the August edition of the journal Lancet Neurology.
Related Links:
Washington University School of Medicine
Latest Molecular Diagnostics News
- New Respiratory Syndromic Testing Panel Provides Fast and Accurate Results
- New Synthetic Biomarker Technology Differentiates Between Prior Zika and Dengue Infections
- Novel Biomarkers to Improve Diagnosis of Renal Cell Carcinoma Subtypes
- RNA-Powered Molecular Test to Help Combat Early-Age Onset Colorectal Cancer
- Advanced Blood Test to Spot Alzheimer's Before Progression to Dementia
- Multi-Omic Noninvasive Urine-Based DNA Test to Improve Bladder Cancer Detection
- First of Its Kind NGS Assay for Precise Detection of BCR::ABL1 Fusion Gene to Enable Personalized Leukemia Treatment
- Urine Test to Revolutionize Lyme Disease Testing
- Simple Blood Test Could Enable First Quantitative Assessments for Future Cerebrovascular Disease
- New Genetic Testing Procedure Combined With Ultrasound Detects High Cardiovascular Risk
- Blood Samples Enhance B-Cell Lymphoma Diagnostics and Prognosis
- Blood Test Predicts Knee Osteoarthritis Eight Years Before Signs Appears On X-Rays
- Blood Test Accurately Predicts Lung Cancer Risk and Reduces Need for Scans
- Unique Autoantibody Signature to Help Diagnose Multiple Sclerosis Years before Symptom Onset
- Blood Test Could Detect HPV-Associated Cancers 10 Years before Clinical Diagnosis
- Low-Cost Point-Of-Care Diagnostic to Expand Access to STI Testing